Spots Global Cancer Trial Database for ds stage iii plasma cell myeloma

Every month we try and update this database with for ds stage iii plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01936090	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom...	18 Years -	Mayo Clinic
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT00066638	DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Romidepsin Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01842308	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Autologous Bone... Autologous Hema... Carfilzomib Laboratory Biom... Melphalan	18 Years -	Mayo Clinic
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant	NCT00839956	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl...	Bortezomib Vorinostat	18 Years -	Fred Hutchinson Cancer Center
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma	NCT00445692	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Clarithromycin Dexamethasone Lenalidomide	18 Years -	Fred Hutchinson Cancer Center
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01605032	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Busulfan Melphalan Bortezomib Autologous Hema... Peripheral Bloo...	18 Years - 72 Years	Albert Einstein College of Medicine
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma	NCT01330173	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Vismodegib Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01936090	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom...	18 Years -	Mayo Clinic
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma	NCT00445692	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Clarithromycin Dexamethasone Lenalidomide	18 Years -	Fred Hutchinson Cancer Center
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT00066638	DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Romidepsin Laboratory Biom...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: